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Abstract
Background: Migraine is considered a neurovascular disorder, but its pathophysiological mechanisms are not yet
fully understood. Adenosine has been shown to increase in plasma during migraine attacks and to induce
vasodilation in several blood vessels; however, it remains unknown whether adenosine can interact with the
trigeminovascular system. Moreover, caffeine, a non-selective adenosine receptor antagonist, is included in many
over the counter anti-headache/migraine treatments.
Methods: This study used the rat closed cranial window method to investigate in vivo the effects of the adenosine
A2A receptor antagonists with varying selectivity over A1 receptors; JNJ-39928122, JNJ-40529749, JNJ-41942914, JNJ-
40064440 or JNJ-41501798 (0.3–10 mg/kg) on the vasodilation of the middle meningeal artery produced by either
CGS21680 (an adenosine A2A receptor agonist) or endogenous CGRP (released by periarterial electrical stimulation).
Results: Regarding the dural meningeal vasodilation produced neurogenically or pharmacologically, all JNJ
antagonists: (i) did not affect neurogenic vasodilation but (ii) blocked the vasodilation produced by CGS21680, with
a blocking potency directly related to their additional affinity for the adenosine A1 receptor.
Conclusions: These results suggest that vascular adenosine A2A (and, to a certain extent, also A1) receptors mediate
the CGS21680-induced meningeal vasodilation. These receptors do not appear to modulate prejunctionally the
sensory release of CGRP. Prevention of meningeal arterial dilation might be predictive for anti-migraine drugs, and
since none of these JNJ antagonists modified per se blood pressure, selective A2A receptor antagonism may offer a
novel approach to antimigraine therapy which remains to be investigated in clinical trials.
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Background
Migraine is a neurovascular disorder associated with ac-
tivation of the trigeminovascular system and release of
calcitonin gene-related peptide (CGRP) from trigeminal
sensory perivascular nerves, which results in cranial
vasodilation and stimulation of sensory nerve transmis-
sion [1]. In line with these neurovascular mechanisms: (i)
plasma levels of CGRP, which increase during migraine,
are normalized by triptans in parallel with amelioration of
headache [2]; and (ii) CGRP receptor antagonists [1] and
antibodies against CGRP or its receptor [3] are
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effective in migraine treatment. Although there seem to
be some full-responders, the average reduction in mi-
graine days compared to placebo is only in the excess of
1 day per month when administering any CGRP anti-
body [4]. This limited efficacy resulting from inhibiting
CGRP effects suggests that the pathogenesis of migraine
could involve additional mechanisms.
Interestingly, adenosine (released centrally and periph-
erally as a breakdown product of ATP) is another neuro-
modulator that seems to play a role in migraine
pathophysiology [5]. Indeed: (i) adenosine plasma levels
have been reported to be increased during migraine at-
tacks [6]; (ii) exogenous adenosine may trigger migraine
attacks [7]; (iii) dipyridamole, an adenosine uptake inhibi-
tor, may increase the frequency of migraine attacks [8];
and (iv) an adenosine gene haplotype has been associated
with migraine with aura [9]. Accordingly, adenosine re-
ceptor antagonists may have potential therapeutic useful-
ness in the treatment of migraine; while caffeine, a
non-selective adenosine receptor antagonist [5], is already
present in several over-the-counter anti-headache/mi-
graine medications [10].
The conjunction of structural, transductional and op-
erational criteria has shown that adenosine can activate
four subtypes of G-protein-coupled receptors [11, 12],
namely adenosine: (i) A1 and A3 receptors (coupled to Gi
proteins), which mediate vascular smooth muscle constric-
tion; and (ii) A2A and A2B receptors (coupled to Gs pro-
teins), which mediate direct and endothelium-dependent
vasodilation [13, 14]. Moreover, the A1 receptor can also
mediate endothelium-dependent vasodilation [15, 16].
Within this framework, it has been shown ex vivo that
adenosine and CGS21680, a stable A2A receptor agonist
(with about 10–100-fold selectivity for A2A receptors
over A1 and A3 receptors and poor affinity for A2B
receptors [17]), dilate middle meningeal and cerebral
arteries respectively, a response blocked by A2A re-
ceptor antagonists [13, 18].
The above findings, coupled to the demonstration that
the trigeminal ganglion expresses A2A receptors [19] and
the ability of this receptor to facilitate CGRP release in the
hippocampus [20], beg the questions of whether adeno-
sine A2A receptors can induce meningeal vasodilation in
vivo, and also whether they could be involved in neuro-
genic vasodilation either per se or as modulators of CGRP
release in the trigeminovascular system.
Hence, this study used the rat closed cranial window
method, a model predictive of antimigraine action [21],
to investigate the effects of five novel adenosine A2A re-
ceptor antagonists (Fig. 1) on the vasodilation of the
middle meningeal artery produced by either CGS21680 or
endogenous CGRP (released by periarterial electrical stimu-
lation). These antagonists (JNJ-41942914, JNJ-39928122,
JNJ-40529749, JNJ-40064440 and JNJ-41501798) were de-
veloped as described by Shook et al. [22] and display a vary-
ing degree of selectivity for A2A over A1 receptors (Table 1).
Methods
Intravital microscopy experiments
Animals
Fifty seven normotensive male Sprague-Dawley rats (300–
400 g), purchased from Harlan (Horst, The Netherlands),
Fig. 1 Molecular structures of the JNJ antagonists from Janssen Research & Development
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were maintained at a 12/12-h light-dark cycle (with light
beginning at 7 a.m.) and housed at a constant temperature
(22 ± 2°C) and humidity (50%), with food and water ad
libitum. Only male rats were used to avoid crosstalk be-
tween CGRP and hormonal fluctuations during the female
oestrus cycle [23]. The animals were anaesthetized with an
intraperitoneal (i.p.) injection of sodium pentobarbital
(60 mg/kg, followed by 18 mg/kg i.v. per hour when ne-
cessary). The adequacy of anaesthesia was judged by a
negative tail flick test and the absence of ocular reflexes,
amongst others. All experimental protocols of this study
were approved by our Institutional Ethics Committee
[Erasmus MC; permission protocol number EMC 1931
(118–09-04)], in accordance with the NIH guide for the
Care and Use of Laboratory Animals in U.S.A. and the
ARRIVE guidelines for reporting experiments in animals
[24]. All rats were randomly assigned into the different ex-
perimental protocols (see experimental protocol section).
General methods
After anesthesia, the trachea was cannulated and connected
to a pressure ventilator (small animal ventilator SAR-830
series, CWE Inc., Ardmore, PA, U.S.A.). End-tidal pCO2
was monitored (Capstar-100 CWE Inc., PA, U.S.A.) and
kept between 35 and 48 mmHg. The left femoral vein and
artery were cannulated for intravenous (i.v.) administration
of drugs and continuous monitoring of blood pressure, re-
spectively. Two or three samples of blood (at the beginning
and at the end of the experiment) were withdrawn via the
femoral artery to monitor blood gases and other parame-
ters, which were kept between normal values (pH: 7.35–
7.48; pCO2: 35–48 mmHg; pO2: 100–120 mmHg). The
body temperature of each rat was monitored via a rectal
thermometer and maintained throughout the experiment
(36.5 °C–37.5 °C) by a homeothermic blanket system for
rodents (Harvard Instruments, Edenbridge, Kent, U.K.).
The rats were placed in a stereotaxic frame and the parietal
bone overlying a segment of the dural meningeal artery was
carefully drilled thin, applying cold saline (4 °C) until the ar-
tery was visible. Since skull drilling induces vasodilation, we
allowed the animal to recover for 1 h before the experimen-
tal protocol. The drilled area was covered with mineral oil
to prevent drying and to facilitate visualization of the men-
ingeal artery. The artery was captured with an intravital
microscope (model MZ 16; Leica microsystem Ltd., Heer-
brugg, Switzerland) using a cyan blue filter on a cold source
of light. A zoom lens (80–450 ×magnification) and a cam-
era was used to display images with the blood vessel diam-
eter (30–40 μm at baseline) being continuously monitored
and measured with a video dimension analyser (Living Sys-
tems Instrumentation Inc., Burlington, VT, U.S.A.). In rats
where periarterial electrical stimulation was used to evoke
dural vasodilation, a bipolar stimulating electrode (NE
200X, Clark Electromedical, Edenbridge, Kent, U.K.) was
placed on the surface of the cranial window approximately
within 200 μm from the vessel of interest. The cranial win-
dow surface was stimulated at 5 Hz, 1 ms for 10 s (Stimula-
tor model S88, Grass Instruments, West Warwick, RI,
U.S.A.). For neurogenic dural vasodilation, we initially
started with a current intensity (monitored on an oscillo-
scope, model 54601A, Hewlett Packard, Palo Alto, CA,
U.S.A.) of 100 μA and increased with 50 μA steps until a
maximal level of dilatation was achieved, usually at 200 μA.
The resulting data were displayed and recorded using a
WINDAQ data acquisition system (Version 2.54; DataQ In-
struments Inc., Akron, OH, U.S.A.).
Experimental protocols
First, 6 animals were used to determine the effect of i.v. ad-
enosine and caffeine on the middle meningeal artery diam-
eter. The doses of adenosine (1 mg/kg) and caffeine
(40 mg/kg) were based on previously published work
[15, 25]. Further, 51 animals were divided into two groups
which received, respectively, periarterial electrical stimula-
tion (150–250 μA; n = 27) and the adenosine A2 receptor
agonist CGS21680 (10 μg/kg, i.v., n = 24; the optimal dose
as determined in 7 pilot experiments, data not shown).
Dural vasodilator responses remained unchanged after re-
peated treatment for 4 times (data not shown) and in the
presence of the vehicle captisol, which was used for dissolv-
ing most of the antagonists. Thirty min were allowed be-
tween each of these treatments for recovery to the baseline
diameter. Subsequently, each of these groups was subdi-
vided into five subgroups (n = 3–6 each) which were given
(after 30 min) i.v. bolus injections of, respectively, the ad-
enosine A2A receptor antagonists JNJ-41942914 (0.3, 1, and
3 mg/kg), JNJ-39928122, JNJ-40529749, JNJ-40064440 and
JNJ-41501798 (all 1, 3 and up to 10 mg/kg). Based on their
binding affinities (see Table 1), only doses up until signifi-
cant blockade, were tested for the CGS21580 response.
Each antagonist dose was administered 5 min before
Table 1 Affinity constants indicated as IC50 in nM (and the
corresponding pIC50) for the compounds used in the present
study
Compound A2A A1 Fold selectivity
Selectivity A2A vs. A1
CGS2168033 22 nM (7.6) 3100 nM (5.5) 141
Caffeine28 8100 nM (5.1) 20,000 nM (4.7) 2.5
JNJ-39928122a 7.9 nM λ (8.1) 55.1 nM λ (7.3) 7
JNJ-40529749a 4.9 nM (8.3) 89.1 nM (7.1) 18
JNJ-41942914a 8.3 nM (8.1) 1093 nM (6.0) 132
JNJ-40064440a 8.2 nM (8.1) 1240 nM (5.9) 151
JNJ-41501798a 11.5 nM (7.9) 7997 nM (5.1) 695
The JNJ antagonists were developed by Johnson & Johnson Pharmaceutical
Research & Development, L.L.C
Hutchison et al. 1989 [33]; Fredholm et al. 1999 [28]; a, Paul Jackson (Janssen
Research & Development, personal communication); λ, Indicates Ki values
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periarterial electrical stimulation or CGS21680, except for
caffeine (15 min) as previously reported [25]. The duration
of each experiment was approximately 2.5 h after
stabilization.
Data presentation and statistical evaluation
All data are presented as mean ± SEM. The peak increases
in dural meningeal artery diameter are expressed as per-
cent change from baseline. Changes in mean arterial blood
pressure (MAP) were expressed as absolute values (mm
Hg). The difference between the variables within one
group was compared by using a one-way repeated mea-
sures analysis of variance followed by Dunnet’s test. Dun-
net’s test does not give individual P-values, hence
statistical significance was accepted at P < 0.05. When
there was only one dose applied (for caffeine), two-tailed
paired Student’s T-test was used.
Drugs
The compounds used in this study were: sodium
pentobarbital (Nembutal; Ceva Sante Animale B.V.,
Maassluis, The Netherlands); caffeine, adenosine and
CGS21680 hydrochloride hydrate (2-p-(2-Carbox-
yethyl)phenethylamino-5′-N-ethylcarboxamido adeno-
sine hydrochloride hydrate) (Sigma Chemicals Co.,
Steinheim, Germany); JNJ-41942914, JNJ-39928122,
JNJ-40064440, JNJ-40529749 and JNJ-41501798 (gift
courtesy from Janssen Research & Development,
L.L.C., Raritan, NJ, U.S.A.). Caffeine, adenosine,
CGS21680 and JNJ-40064440 were dissolved in dis-
tilled water, whereas JNJ-39928122, JNJ-41942914,
JNJ-40529749 and JNJ-41501798 were dissolved in
captisol (sulfobutylether β-cyclodextrin; Ligand Phar-
maceuticals, San Diego, U.S.A.). The suspensions of
JNJ-40529749 and JNJ-41501798 were sonicated and
filtrated. All solutions were further diluted in saline.
Results
General considerations
In order to facilitate the interpretation of the following
results, the five JNJ antagonists (Table 1) were
sub-divided, a priori, into 3 groups (indicated in different
grey-tones): (i) JNJ-39928122 and JNJ-40529749 have ~
10 fold selectivity for A2A over A1 receptors; (ii)
JNJ-41942914 and JNJ-40064440 are ~ 100 fold selective
for A2A over A1 receptors; and (iii) JNJ-41501798 is ~
700 fold selective for A2A over A1 receptors. It is also
worth mentioning that caffeine has ~ 2.5 fold selectivity
for the rat and ~ 5 fold selectivity for the human A2A vs.
A1 receptors [KD values, [26]]; however, caffeine also in-
hibits A2B receptor with similar affinity as for A1, which is
not the case for the JNJ antagonists.
Effects of i.v. adenosine and caffeine on dural diameter
and MAP
We initially set out to determine the effect of adenosine on
the dural diameter in vivo. Figure 2 shows that (i) 1 mg/kg
adenosine caused a dural artery dilation of 50 ± 6% and a
drop in blood pressure to 53 ± 4 mmHg; (ii) 40 mg/kg caf-
feine caused a non-significant dural artery dilation of 12 ±
5%, while blood pressure was increased significantly by 14
± 3 mmHg; (iii) after a stabilizing period post-caffeine, the
second dural artery dilation produced by adenosine was re-
duced to 25 ± 6% (n = 6, p = 0.003, which was accompanied
by a significantly attenuated drop in blood pressure, to 69
± 5 mmHg (p = 0.004).
Effect of the JNJ antagonists on the dural dilatation by
periarterial electrical stimulation
In order to investigate whether the dural dilation induced by
periarterial electrical stimulation could be in part dependent
on adenosine release, either as direct activation of
vascular adenosine receptors or prejunctional modulation
Fig. 2 The effect of caffeine on adenosine-induced dural vasodilation. Adenosine (1 mg/kg) was injected i.v. after a recovery period of 30 min. Then,
caffeine (40 mg/kg) was injected slowly, and a second adenosine injection (1 mg/kg) was injected 15 min after the caffeine injection (adenosine after
caffeine). Left panel illustrates increase in diameter and right panel changes in mean arterial blood pressure, in response to adenosine. Data are ± SEM,
n = 6, ** p < 0.01 compared to the control. Open circles represent baseline measurements before injections, B=Baseline
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of trigeminal CGRP release, the JNJ antagonists (given i.v.)
were investigated in their capability to modify the dural
vasodilation produced by electrical stimulation. As shown
in Fig. 3 (left panels), neurogenic stimulation induced,
overall, an immediate increase in dural artery diameter of
83 ± 7% (n = 27). Surprisingly, none of the JNJ antagonists
affected this neurogenic vasodilation (left panels). Suggest-
ing that neither A1 nor A2A receptors are involved.
Fig. 3 Effect of A2A antagonists on perivascular electrical stimulation of the dural artery. Perivascular electrical stimulation (150–250 μA) in the
absence or presence of vehicle, or varying doses of JNJ-39928122 (A, n = 4), JNJ-40529749 (B, n = 4–5), JNJ-41942914 (C, n = 6), JNJ-40064440 (D,
n = 4), or JNJ-41501798 (E, n = 7–8). Data are presented as percentage of increase in diameter, left panels) and changes in mean arterial blood
pressure (mm Hg, right panels) induced by periarterial electrical stimulation (ES). Note that none of the treatments produced any significant
changes (p > 0.05 compared to the vehicle). Open circles represent baseline measurements before injections/ES. JNJ-40064440 was dissolved in
water, so vehicle measurements equal control
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The effect of the JNJ antagonists on MAP before and
during neurogenic dural stimulation
As shown in Fig. 3 (right panels), both periarterial elec-
trical stimulation and the JNJ antagonists were devoid of
any effect per se on MAP.
Effects of CGS21680 on dural artery diameter and MAP
Although adenosine A2A or A1 receptors did not appear to
be important in the vasodilation observed after neurogenic
dural stimulation, adenosine vasodilates dural arteries in
vivo (Fig. 2), most likely via both A2A and A2B receptors as
previously reported ex vivo [13]. Since our study set out to
study specifically the role of the adenosine A2A receptor, we
continued our study using CGS21680, which is a more bio-
logically stable, highly selective for A2A over A2B receptor
agonist [17].
As shown in Fig. 4, CGS21680 (10 μg/kg before adminis-
tration of JNJ antagonists; n = 24) mimicked adenosine in
its capability to produce: (i) a marked dilation of the dural
artery diameter (66 ± 9%; left panels); and (ii) a drop in
blood pressure (53 ± 9 mmHg; right panels) and hence ex-
cluding the involvement of A2B receptors.
The lower the selectivity (A2A over A1 receptors) the
higher the potency of JNJ antagonists to block
CGS21680-induced dural vasodilation
To further uncover the nature of the adenosine recep-
tors in the dural vasculature, we explored the effect of
the JNJ antagonist with varying selectivity (A2A over A1
receptors). Figure 4 (left panels) also shows that all JNJ
antagonists significantly blocked the CGS21680-induced
dural vasodilation with varying degrees of potency. Spe-
cifically, the vasodilation to CGS21680 was: (i) abolished
by 1 mg/kg (− 1 ± 2%) of JNJ-39928122 (Fig. 4a); (ii)
abolished at 1 mg/kg (− 2 ± 1%) of JNJ-40529749 (Fig.
4b); (iii) significantly attenuated (but not abolished) by
3 mg/kg (21 ± 11%) of JNJ-41942914 (Fig. 4c); (iv) sig-
nificantly attenuated by 3 mg/kg (23 ± 15%) and abol-
ished (1 ± 3%) by 10 mg/kg of JNJ-40064440 (Fig. 4d);
and (v) dose-dependently blocked, and practically abol-
ished by 10 mg/kg (5 ± 4%) of JNJ-41501798 (Fig. 4e).
Clearly, the lower the selectivity of A2A vs. A1 (Table 1)
the higher the potency of JNJ antagonists to block
CGS21680-induced dural vasodilation.
Effect of JNJ antagonists on CGS21680-induced
vasodepressor responses
Similarly, the vasodepressor responses to CGS21680
were blocked by the JNJ antagonists as follows: (i) very
potently by the less selective antagonists JNJ-39928122
and JNJ-40529749; and (ii) less potently by the highest
doses of the more selective antagonists JNJ-41942914,
JNJ-40064440 and JNJ-41501798, which display from
low to very low affinity for the A1 receptor (Table 1).
Discussion
Comparison between in vivo and in vitro vascular
responses to adenosine
The adenosine receptor antagonists SCH58261 (478-fold
A2A over A1 selective [27]) and caffeine (non-selective
A1/2A/2B [28]) have been shown to block the ex vivo
adenosine-induced dilation of endothelium-denuded
middle meningeal arteries [18]. In these experiments,
not only did caffeine (50 μM) or SCH58261 (1 μM) pre-
vent the dural dilation, but a vasoconstriction to adeno-
sine was unmasked. Interestingly, this effect was not
observed in vivo, which could be due to the fact that the
artery used for the myograph (outer diameter ~ 100 μm)
had a larger diameter than in this study (outer diameter
~ 35 μm) and that there potentially are less A3 receptors
expressed in smaller vessels, as we see no indirect in-
volvement of A3 (i.e. vasoconstriction) in the current ex-
periments. These differences require further
investigation, but it is known that receptor expression
changes along different vascular beds [29].
General considerations
In addition to the implications discussed below, the present
study shows that: (i) both adenosine and CGS21680 pro-
duced rat dural vasodilation in vivo; and (ii) for JNJ antago-
nists, the lower the selectivity (A2A over A1 receptors) the
higher the potency to block the dural vasodilation and
vasodepressor responses induced by CGS21680 (implying
that blockade of A1 receptors is also necessary to com-
pletely block the dural vasodilation in vivo). The latter find-
ing is most likely due to endothelial A1 receptors, as the
main difference between the in vivo (present study) and the
ex vivo studies [18] is the absence of endothelium. Indeed,
Honey et al. [21] have shown the presence of adenosine A1
receptors mediating vasodilation in the rat middle menin-
geal artery in vivo.
The potential role of A2A and A1 receptors in the dural
vasodilation as prejunctional modulators of neurogenic
dural vasodilation or produced by CGS21680
The simplest interpretation of the fact that the JNJ an-
tagonists had no effect on neurogenic dural vasodilation
(Fig. 3), which involves CGRP release [1], implies that:
(i) adenosine is not released by periarterial electrical
stimulation; (ii) A2A receptors do not constitute a posi-
tive feedback mechanism for CGRP release, as expected
from its transductional properties (positive coupling to
Gs proteins; [11]); or (iii) cAMP increase, induced by
CGRP, is so high that this could have masked the small
increase in cAMP levels mediated by A2A receptors [26].
Interestingly, adenosine A1 receptors [coupled to Gi
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proteins; [11]] can produce a prejunctional inhibition of
the neurogenic dural vasodilation in rats [21]. However,
the weakly selective JNJ antagonists (JNJ-39928122 and
JNJ-40529749), which would be theoretically expected to
block (at least in part) this mechanism, did not increase
neurogenic dural vasodilation (Fig. 3).
Several lines of evidence have previously shown in
other systems that: (i) the vasodilation produced by ad-
enosine and related agonists is mainly mediated by vas-
cular and endothelial A2A receptors [13, 14] as well as
by endothelial A1 receptors [16]; and (ii) the trigemino-
vascular system expresses A2A receptors [19]. In keeping
Fig. 4 Effect of i.v. CGS21680 on the dural diameter. CGS21680 (10 μg/kg) was injected followed by an injection of vehicle and varying doses of
JNJ-39928122 (a), n = 5, Dunnet critical value: 1014), JNJ-40529749 (b), n = 3–5, Dunnet critical value: 3791) JNJ-41942914 (c), n = 4, Dunnet critical
value: 6008), JNJ-40064440 (d), n = 3–4, Dunnet critical value: 8446), or JNJ-41501798 (e), n = 5–6, Dunnet critical value: 5848). Data are presented
as percentage of increase in diameter (left panels) and changes in mean arterial blood pressure (mm Hg, right panels) induced by CGS21680 (left
lower panels). CGS, 10 μg/kg CGS21680 i.v.; * p < 0.05, ** p < 0.01, *** p < 0.001 compared to the vehicle. #CGS in presence of vehicle. Open circles
represent baseline measurements before injections. JNJ-40064440 was dissolved in water, so vehicle measurements equal control
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with these findings, our results further demonstrate that
the JNJ antagonists blocked CGS21680-induced dural
vasodilation (Fig. 4), with a different profile of blockade
(dependent on A2A vs. A1 selectivity; see below). This re-
inforces the involvement of adenosine A2A and, probably
to a lesser extent, of A1 receptors. In addition, based on
the poor affinity of CGS21680 for the A2B receptors [17]
and similar responses to adenosine, our data did not
show any strong involvement of the A2B receptors.
Systemic effects of JNJ antagonists on A2A and A1
receptors
Caffeine is a non-selective adenosine A1, A2A and A2B
receptor antagonist that does not affect A3 receptors at
the doses used [28]. Accordingly, caffeine produced a
slight increase in blood pressure (Fig. 2), as previously
reported [25]. Interestingly, the fact that none of the JNJ
antagonists increased blood pressure (Fig. 4, right panel),
even at doses that blocked the dural vasodilation to
CGS21680 (Fig. 4, left panel) suggests that there is no
strong “adenosine vascular tone”. In addition, it is worth
emphasizing that A2B receptors are involved in the blood
pressure effects of adenosine [30], which would explain
the minor difference between caffeine and the JNJ antag-
onists in our study.
It is well established that A2A receptor agonists lower
blood pressure [12, 31]. The A1 receptor agonists
GR79236 and N6-cyclopentyladenosine (CPA), although
less studied, also decrease blood pressure with higher
potency than CGS21680, and both cause direct produc-
tion of endothelial NO [15, 16, 31]. Hence, the vasode-
pressor response to adenosine in A1 −/− mice is reduced
[32]. In the present study, the less selective
(JNJ-39928122 and JNJ-40529749) A2A vs. A1 antago-
nists potently blocked the decrease in blood pressure,
whereas the more selective (JNJ-40064440 and
JNJ-41501798) A2A antagonists were less potent, and
only effective at 10 mg/kg. These high doses of
JNJ-4006440 and JNJ-41501798 also induced inihibition
of A1 receptors. Blockade of the adenosine A2A and A1
receptors prevents systemic vasodilation in response to
adenosine, and therefore the block in blood pressure.
In vivo effects of CGS21680
In binding affinity studies, CGS21680 is 141-fold select-
ive for A2A over A1 receptors [33]. However, our study
raises the concern whether CGS21680 is a specific A2A
receptor agonist in vivo in rats, as it appears that higher
blocking affinities for the A1 receptor causes a more po-
tent blockade of the vasodepressor and dural vasodilator
responses. For the human adenosine receptors, the se-
lectivity for A2A over A1 receptors is minimal [34].
The most obvious explanation for the apparent dis-
crepancy between the binding affinity selectively and the
in vivo effects, is the location of adenosine receptors, as
A1 receptors are on the endothelium, whereas the A2A
receptors are mainly located on vascular smooth muscle
[12]; hence the endothelium will be directly exposed to
an apparently higher concentration. In addition, there
are opposing findings on the selectivity of CGS21680.
For example CGS21680 binds with high affinity (around
1 nM) to A1 receptors in the hippocampus of A2A−/−
mice [35], in contrast, in the same mice CGS21680 had
no effect on blood pressure [36].
Comparing our findings with previous studies in rats, the
vasodepressor response to CGS21680 (10 μg/kg) was com-
pletely blocked by 3 mg/kg of the A2A receptor antagonists
ZM241385 [319-fold A2A over A1; [15, 27]] or CGS15943
[9-fold A2A over A1; [37]]. Clearly, ZM241385 has a higher
A2A over A1 selectivity, but its Ki for A1 receptors is
255 nM. Since these binding data are similar to those of
our less selective compounds, A2A and also A1 receptors
would be blocked in these studies.
Possible clinical implications
On the basis of the above lines of evidence, the antimi-
graine potential of selective adenosine A2A receptor antago-
nists would be of particular relevance in those patients
whose adenosine plasma levels are markedly increased dur-
ing a migraine attack. Although our findings indicate that
adenosine is not released by perivascular electrical stimula-
tion, inhibition of dural vasodilation is a shared mechanism
of current (ergots and triptans) and prospective (CGRP (re-
ceptor) antagonists and antibodies) antimigraine drugs [1,
38]. Whether this (antimigraine) mechanism alone is suffi-
cient to attenuate the trigeminal nociceptive transmission
associated with migraine headache, remains to be deter-
mined. Additionally, other studies have shown that: (i) acti-
vation of A2A receptors facilitates the action of CGRP and
VIP in the rat hippocampus [20]; (ii) A2A receptor knock-
out mice are hypoalgesic [36]; and (iii) A2A receptors are
expressed in the rat trigeminovascular system [19] as well
as in the rat trigeminal ganglion, together with A1, A2B and
A3 receptors [18]. Furthermore, intra-articular administra-
tion of adenosine and N6-cyclohexyladenosine (CHA, an
adenosine A1 receptor agonist), but not CGS21680, signifi-
cantly increased ketorolac antinociception [39]. These find-
ings, taken together: (i) argue in favor of selective blockade
of adenosine A2 receptors as a potential antimigraine strat-
egy; and (ii) imply that blockade of A1 receptors would be a
disadvantage in antimigraine treatment. Obviously, further
clinical studies should evaluate the JNJ antagonist(s) with
the optimal oral bioavailability based on their pharmacoki-
netic properties.
Conclusions
In conclusion, all the JNJ antagonists were capable of
blocking CGS21680-induced dural vasodilation without
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affecting neurogenic dural vasodilation (suggesting no
modulation of trigeminal CGRP release). This blockade
was more potent when showing lower A2A over A1 se-
lectivity, and that both these receptors are involved in
the dural artery vasodilation. On this basis, and consid-
ering that the JNJ antagonist were devoid of any effect
per se on blood pressure, selective A2A receptor antag-
onism may offer a novel approach to antimigraine ther-
apy that remains to be determined in clinical trials.
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